ReviewTouchREVIEWS in endocrinology2023

Resmetirom: An Orally Administered, Smallmolecule, Liver-directed, β-selective THR Agonist for the Treatment of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis.

Gres Karim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.